Al-Khami Amir A, Mehrotra Shikhar, Nishimura Michael I
Division of General Surgery; Department of Surgery; Medical University of South Carolina; Charleston, SC USA.
Self Nonself. 2011 Apr;2(2):80-84. doi: 10.4161/self.2.2.15832. Epub 2011 Apr 1.
Adoptive transfer of tumor-reactive T cells has emerged as a promising advance in tumor immunotherapy. Specifically, infusion of tumor-infiltrating lymphocytes has led to long-term objective clinical responses for patients with metastatic melanoma. Donor lymphocyte infusion is also an effective treatment of post-transplant lymphoproliferative disease. However, adoptive T cell therapy has restrictions in the isolation and expansion of antigen-specific lymphocytes for a large group of patients. One approach to circumvent this limitation and extend adoptive immunotherapy to other cancer types is the genetic modification of T cells with antigen-specific receptors. In this article, we review strategies to redirect T cell specificity, including T cell receptor gene transfer and antibody receptor gene transfer.
肿瘤反应性T细胞的过继性转移已成为肿瘤免疫治疗中一项有前景的进展。具体而言，输注肿瘤浸润淋巴细胞已使转移性黑色素瘤患者获得了长期客观的临床反应。供体淋巴细胞输注也是治疗移植后淋巴细胞增殖性疾病的有效方法。然而，过继性T细胞疗法在为大量患者分离和扩增抗原特异性淋巴细胞方面存在限制。一种克服这一限制并将过继性免疫疗法扩展到其他癌症类型的方法是用抗原特异性受体对T细胞进行基因改造。在本文中，我们综述了重定向T细胞特异性的策略，包括T细胞受体基因转移和抗体受体基因转移。
